Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Delafloxacin 1-(6-amino-3,5-difluoro- pyridin-2-yl)-8...

Synonyms: QCR-52, AC1LAFLM, ABT-492, S1553_Selleck, ABT492, ...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of WQ-3034

In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [1].
ABT-492 exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs (in micrograms per milliliter) at which 90% of the isolates tested were inhibited as follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008; and Streptococcus pneumoniae, 0.015 [2].
In particular, ABT-492 was more active than trovafloxacin and levofloxacin against multidrug-resistant Streptococcus pneumoniae, including strains resistant to penicillin and macrolides, and H. influenzae, including beta-lactam-resistant strains [3].
The profile of ABT-492 suggested that it may be a useful agent for the treatment of community-acquired respiratory tract infections, as well as infections of the urinary tract, bloodstream, and skin and skin structure and nosocomial lung infections [3].
In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis [2].

High impact information on WQ-3034

Both ABT-492 and levofloxacin demonstrated concentration-dependent bactericidal activities in time-kill kinetics studies at four and eight times the MIC with 10 of 12 bacterial isolates exposed to ABT-492 and with 12 of 12 bacterial isolates exposed to levofloxacin [1].
ABT-492 was a potent inhibitor of bacterial topoisomerases, and unlike the comparators, DNA gyrase and topoisomerase IV from either Staphylococcus aureus or Escherichia coli were almost equally sensitive to ABT-492 [3].
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex [4].
The one isolate of H. influenzae tested with reduced fluoroquinolone susceptibility had an ABT-492 MIC close to that of the population lacking a mechanism of quinolone resistance [5].
Determination of in vitro susceptibility to ABT-492 by BSAC standardized methodology [6].

References

In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Gunderson, S.M., Hayes, R.A., Quinn, J.P., Danziger, L.H. Antimicrob. Agents Chemother. (2004) [Pubmed]
In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Goldstein, E.J., Citron, D.M., Merriam, C.V., Warren, Y.A., Tyrrell, K.L., Fernandez, H.T. Antimicrob. Agents Chemother. (2003) [Pubmed]
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Nilius, A.M., Shen, L.L., Hensey-Rudloff, D., Almer, L.S., Beyer, J.M., Balli, D.J., Cai, Y., Flamm, R.K. Antimicrob. Agents Chemother. (2003) [Pubmed]
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tomioka, H., Sato, K., Kajitani, H., Akaki, T., Shishido, S. Antimicrob. Agents Chemother. (2000) [Pubmed]
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. Harnett, S.J., Fraise, A.P., Andrews, J.M., Jevons, G., Brenwald, N.P., Wise, R. J. Antimicrob. Chemother. (2004) [Pubmed]
Determination of in vitro susceptibility to ABT-492 by BSAC standardized methodology. Andrews, J.M., Ashby, J.P., Jevons, G., Wise, R. J. Antimicrob. Chemother. (2003) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share